

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA

**Ibrutinib with R-CHOP for untreated mantle cell lymphoma
when an autologous stem cell transplant is suitable**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

- | | |
|----|--|
| 1. | Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they? |
|----|--|

No potential equality issues have been identified during the scoping process.

- | | |
|----|--|
| 2. | What is the preliminary view as to what extent these potential equality issues need addressing by the committee? |
|----|--|

N/A

- | | |
|----|---|
| 3. | Has any change to the draft scope been agreed to highlight potential equality issues? |
|----|---|

No

- | | |
|----|---|
| 4. | Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made? |
|----|---|

Cancer Equality has been added to the stakeholder list.

Approved by Associate Director (name): Ian Watson

Date: 27 October 2025